English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background  The X-ray repair cross-complementing group 3 (XRCC3) in homologous recombination repair (HRR) pathway plays a very important role in DNA double-strand break repair (DSBR). Variations in the  XRCC3  gene might lead to altered protein structure or function which may change DSBR efficiency and result in cancer. The  XRCC3  C18067T polymorphism has been reported to be associated with skin cancer susceptibility, yet the results of these previous results have been inconsistent or controversial. To derive a more precise estimation of the association, we conducted a meta-analysis.    Methods  The quality of the studies was assessed according to a predefined scale. The association between the  XRCC3  C18067T polymorphism and skin cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs).    Results  Overall, no significant association was observed between  XRCC3  C18067T polymorphism and skin cancer risk in any genetic model. Stratified analyses according to tumor type, significant association was found in the relationship between  XRCC3  C18067T polymorphism and nonmelanoma skin cancer risk (homozygote comparison TT versus CC: OR = 0.74, 95%CI = 0.61–0.90,  P  = 0.003; recessive model TT versus TC/CC: OR = 0.81, 95%CI = 0.68–0.95,  P  = 0.01). Furthermore, significant association was also observed in  XRCC3  C18067T polymorphism with both basal cell carcinoma risk (homozygote comparison TT versus CC: OR = 0.70, 95%CI = 0.53–0.92,  P  = 0.011; recessive model TT versus. TC/CC: OR = 0.74, 95%CI = 0.60–0.92,  P  = 0.007) and squamous cell carcinoma risk (heterozygote comparison TT versus .CC: OR = 0.81, 95%CI = 0.67–0.99,  P  = 0.04; dominant model TT/TC versus .CC: OR = 0.81, 95%CI = 0.68–0.98,  P  = 0.029).    Conclusion  The present meta-analysis demonstrates that  XRCC3  C18067T polymorphism was not associated with risk of cutaneous melanoma but contributed a decreased risk to both basal cell carcinoma and squamous cell carcinoma.

XRCC3 C18067T Polymorphism Contributes a Decreased Risk to Both Basal Cell Carcinoma and Squamous Cell Carcinoma: Evidence from a Meta-Analysis